Literature DB >> 10694836

Bisoprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life.

C J Bulpitt1, M Connor, M Schulte, A E Fletcher.   

Abstract

Subjects over the age 60 with sustained sitting diastolic pressures of 95-115 mm Hg were randomised to a regime based on bisoprolol (n = 368) or nifedipine retard (n = 379) for 24 weeks. The goal diastolic pressure was < or =90 mm Hg and to achieve this, double-blind medication could be doubled (5/10 mg bisoprolol, 40/80 mg nifedipine retard) or hydrochlorothiazide 25 mg (unblinded) could be added to the higher dose. In an intention-to-treat analysis, 309 subjects in both the bisoprolol and nifedipine retard treated group provided at least a baseline and a second quality of life assessment (82%). An excess of symptoms was observed in the nifedipine group for oedema of the legs, nocturia, constipation, racing heart and heart thumping. Fewer patients reported wheeze in the nifedipine group. For quality of life, there were no statistically significant differences between the two groups after 8 weeks. However, when analysing the results of the last available assessment (usually at 24 weeks) there were significant (P < 0.05) improvements in tension/anxiety, anger/ hostility, vigour/activity, and confusion/bewilderment, assessed by the Profile of Mood States (POMS) in patients receiving bisoprolol in comparison to those receiving nifedipine retard. The Sickness Impact Profile and objective tests of cognitive function did not differ statistically between the two groups. Quality of life was maintained at a good level on both treatments with advantages for bisoprolol in certain areas. Journal of Human Hypertension (2000) 14, 205-212.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694836     DOI: 10.1038/sj.jhh.1000972

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  [The emotional sensitivity of elderly people--validation of the Profile of Mood States for people over 60 years].

Authors:  C Albani; T Gunzelmann; G Schmutzer; N Grulke; H Bailer; G Blaser; M Geyer; E Brähler
Journal:  Z Gerontol Geriatr       Date:  2005-12       Impact factor: 1.281

Review 2.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 3.  The relationship between quality of life and adherence to treatment.

Authors:  M I Nunes
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 4.  Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions.

Authors:  Ritu K Soni; Anna C Porter; James P Lash; Mark L Unruh
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

Review 5.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.

Authors:  J Tisaire-Sánchez; J Roma; Ignacio Camacho-Azcargorta; J Bueno-Gómez; J Mora-Maciá; Angel Navarro
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Bisoprolol, Known to Be a Selective β₁-Receptor Antagonist, Differentially but Directly Suppresses IK(M) and IK(erg) in Pituitary Cells and Hippocampal Neurons.

Authors:  Edmund Cheung So; Ning-Ping Foo; Shun Yao Ko; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.